Skip to main content

Dr. Peter A. Merkel, MD, MPH

Rheumatology (Rheumatology Physician)

  • Medicare participating

At a glance

Years since graduation
38
In the NPI registry since
2005
Medicare patients seen, 2024
59

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1988Medical school: Yale University School of Medicine
  • 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Rheumatology Physician primary
    PA license MD043272L · MA license 75719
  • Internal Medicine Physician
    MA license 75719

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Rheumatology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
59
Services billed
163
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes3526
Established patient office or other outpatient visit, 40-54 minutes2018

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Payments from drug and device companies

In 2025, 13 companies reported 36 payments worth $71,402 in total to this clinician.

By type
Consulting Fee$70,920
Food and Beverage$427
Education$54.99

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jun 26, 2025Ns Pharma, Inc.
Jun 26, 2025
Consulting Fee$12,675
Oct 30, 2025Ns Pharma, Inc.
Oct 30, 2025
Consulting Fee$8,400
Jan 10, 2025Ns Pharma, Inc.
Jan 10, 2025
Consulting Fee$6,563
Nov 26, 2025Alexion Pharmaceuticals, Inc.
Nov 26, 2025
Consulting Fee$3,900
Jul 31, 2025Ns Pharma, Inc.
Jul 31, 2025
Consulting Fee$3,850
Dec 17, 2025Amgen Inc.
Dec 17, 2025
Consulting Fee
BLINCYTO · Oncology
$3,500
Oct 31, 2025Alexion Pharmaceuticals, Inc.
Oct 31, 2025
Consulting Fee$3,250
Nov 12, 2025Alexion Pharmaceuticals, Inc.
Nov 12, 2025
Consulting Fee$3,250
Sep 2, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Sep 2, 2025
Consulting Fee$2,800
Feb 5, 2025Argenx US, Inc.
Feb 5, 2025
Consulting Fee$2,800
All 26 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 18, 2025Eli Lilly and Company
Dec 18, 2025
Consulting Fee
Company’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES
$1,200
Dec 17, 2025Amgen Inc.
Dec 17, 2025
Consulting Fee
BLINCYTO · Oncology
$3,500
Nov 26, 2025Alexion Pharmaceuticals, Inc.
Nov 26, 2025
Consulting Fee$3,900
Nov 12, 2025Alexion Pharmaceuticals, Inc.
Nov 12, 2025
Consulting Fee$3,250
Nov 7, 2025Amgen Inc.
Nov 7, 2025
Consulting Fee
TAVNEOS · Inflammation
$1,225
Oct 31, 2025Alexion Pharmaceuticals, Inc.
Oct 31, 2025
Consulting Fee$3,250
Oct 30, 2025Ns Pharma, Inc.
Oct 30, 2025
Consulting Fee$8,400
Oct 27, 2025Janssen Biotech, Inc.
Oct 27, 2025
Education
TREMFYA · Immunology · in-kind
$54.99
Sep 15, 2025Alexion Pharmaceuticals, Inc.
Sep 15, 2025
Consulting Fee$1,463
Sep 2, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Sep 2, 2025
Consulting Fee$2,800
Aug 11, 2025Amgen Inc.
Aug 11, 2025
Consulting Fee
TAVNEOS · Inflammation
$1,050
Aug 7, 2025Amgen Inc.
Aug 7, 2025
Consulting Fee
TAVNEOS · Inflammation
$1,050
Jul 31, 2025Ns Pharma, Inc.
Jul 31, 2025
Consulting Fee$3,850
Jul 25, 2025AbbVie Inc.
Jul 25, 2025
Consulting Fee$2,100
Jul 14, 2025Alexion Pharmaceuticals, Inc.
Jul 14, 2025
Consulting Fee$650
Jul 9, 2025Alexion Pharmaceuticals, Inc.
Jul 9, 2025
Consulting Fee$1,625
Jun 26, 2025Ns Pharma, Inc.
Jun 26, 2025
Consulting Fee$12,675
Jun 26, 2025Alexion Pharmaceuticals, Inc.
Jun 26, 2025
Consulting Fee$650
Apr 16, 2025Alexion Pharmaceuticals, Inc.
Apr 16, 2025
Consulting Fee$1,950
Feb 24, 2025AstraZeneca Pharmaceuticals LP
Feb 24, 2025
Consulting Fee
FASENRA · Respiratory
$1,950
Feb 14, 2025Boehringer Ingelheim Pharmaceuticals, Inc.
Feb 14, 2025
Consulting Fee$2,320
Feb 6, 2025Otsuka Pharmaceutical Development & Commercialization, Inc.
Feb 6, 2025
Consulting Fee$700
Feb 5, 2025Argenx US, Inc.
Feb 5, 2025
Consulting Fee$2,800
Feb 5, 2025Argenx US, Inc.
Feb 5, 2025
Consulting Fee$700
Jan 10, 2025Ns Pharma, Inc.
Jan 10, 2025
Consulting Fee$6,563
Jan 6, 2025AstraZeneca UK Limited
Jan 6, 2025
Consulting Fee$1,300

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Pennsylvania →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $544,931 in research payments for these studies, mostly to the institutions running them.

  • Vasculitis Clinical Research Consortium Eosinophilic Granulomatosis with Polyangiitis Registry
    AstraZeneca Pharmaceuticals LP
  • A Randomized Double-Blind, Placebo Controlled Trial of Abatacept (CTLA4-Ig) in Giant Cell Arteritis (ABAGART)
    E.r. Squibb & Sons, L.l.c.
  • A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamid…
    Amgen Inc.
  • A Randomised, Double-blind, Active-controlled 52-week Study with an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab Compared to Mepolizumab in the Treatment of Eosinophilic Granulomatosis with…
    AstraZeneca Pharmaceuticals LP
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
    AbbVie Inc. · Completed · NCT03725202
  • M16-852 - A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis
    AbbVie Inc.
  • A 52-week, randomized, double-blind, double-dummy, parallel-group, mul
    GlaxoSmithKline, LLC.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Rheumatology clinicians in Radnor

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 3, 2012), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1437136173. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.